A number of new formulations contain small, fine and ultrafine particles of PEA. Due to the fact that GLP studies done with PEA and evaluating its toxicity were not that recent, a whole series of new experiments were done with microPEA (PEA of highest purity, containing small, fine and ultrafine particles). The entire study can be found under the link:
The PEA containing small, fine and ultrafine PEA particles was found to be very safe, even in high dose. This is important news, as some of the high quality formulations containing such PEA are currently frequently prescribed (um-PEA, m-PEA and PEA-opt).
The results from rodent studies show that the previous and present acute oral toxicity studies are in agreement (Masek 1980; Biolabs, 1992b; Intox, 2015c), and repeat oral toxicity studies consistently show an absence of adverse effects at the highest doses tested (Masek 1980, Intox, 2015d, 2016).
In summary, available data from rodent and human studies support the safety of PEA in general, and of microPEA specically, in products intended for human and companion animal consumption.
This recent study once more underlines the safety of this natural fatty compound, this autacoid. Most human studies have been conducted evaluating the dose range around 1200 mg, however, higher doses up to 2400 mg/day also generated no side effects.